Clinical efficacy and safety of neratinib for breast cancer | DDDT – Dove Medical Press

Introduction
Breast cancer is the most common malignancy in women (approximately 30% of total), where it represents the first cause of cancer-related death.1
From a biological point of view, breast cancer can be classified into molecularly defined subtypes,…

Click here to view the original article.